Literature DB >> 15467039

Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Christopher C Parker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15467039     DOI： 10.1093/jnci/djh294

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  The evolving biology and treatment of prostate cancer.

Authors:  Russel S Taichman; Robert D Loberg; Rohit Mehra; Kenneth J Pienta
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 2.  Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

Authors:  Sohita Dhillon; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.

Authors:  Kristen D Brubaker; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  BMC Cancer       Date:  2006-01-17       Impact factor: 4.430

4.  Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.

Authors:  Johanna M Tuomela; Maija P Valta; Kalervo Väänänen; Pirkko L Härkönen
Journal:  BMC Cancer       Date:  2008-03-28       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.